Navigation Links
Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
Date:11/15/2007

rowth of harmful bacteria and fungi. The trials are designed to demonstrate the effectiveness of copper surfaces in reducing the colonization of HVAC systems by harmful microbes and reducing exposure to these organisms throughout the buildings served by the systems.

Laboratory studies are taking place at the University of South Carolina in the Arnold School of Public Health. Field trials will be performed at the Moncrief Army Community Hospital and barracks at Fort Jackson, the D.D. Eisenhower Army Medical Center at Fort Gordon and the United States Air Force Academy. Michels says, "The results of these real-world trials should encourage a leap forward in the design of HVAC systems and make a major contribution to the reduction of Sick Building Syndrome and the improvement of indoor air quality."

The Copper Development Association is the information, education, market and technical development arm of the copper, brass and bronze industries in the USA.


'/>"/>
SOURCE Copper Development Association
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
2. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
3. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. California Legislature Passes Historic HIV Testing Bill (AB 682); AHF Urges Governor to Sign Crucial Lifesaving Legislation
8. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
9. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
10. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
11. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10Reportlinker Adds Training Manikins - Global Trends 2Reportlinker Adds Training Manikins - Global Trends 3Reportlinker Adds Training Manikins - Global Trends 4Reportlinker Adds Training Manikins - Global Trends 5RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3Sinovac Files Shelf Registration Statement 6367 1Sinovac Files Shelf Registration Statement 6367 2Sinovac Files Shelf Registration Statement 6367 3Rules Based Medicine Forms Biomarker Alliance With Covance Inc 6363 1Rules Based Medicine Forms Biomarker Alliance With Covance Inc 6363 2Rules Based Medicine Forms Biomarker Alliance With Covance Inc 6363 3Findings that should speed the development of drugs for Parkinsons disease 61614 1Findings that should speed the development of drugs for Parkinsons disease 61614 2